AZD1208

Description: AZD1208 is a novel, highly selective, ATP-competitive and orally bioavailable small molecule pan-inhibitor of Pim kinase with potential antitumor activity. It inhibits Pim1, Pim2, and Pim3 with IC50s of 0.4 nM, 5 nM, and 1.9 nM in cell-free assays, respectively. As a Pan-PIM kinase inhibitor, AZD1208 demonstrated a broad spectrum of antineoplastic activity against various cancers such as breast, prostate, AML, and non-Hodgkin lymphomas. The mechanism of action of AZD1208 is to inhibit the activities of PIM1/2/3 serine/threonine kinases, which may result in the interruption of the G1/S phase of cell cycle transition, therefore causing cell cycle arrest and inducing apoptosis in cells that overexpress PIMs.

References: Blood. 2014 Feb 6; 123(6):905-13; J Natl Cancer Inst. 2015 Feb; 107(2): dju407; Mol Cancer. 2015; 14: 205.

Related CAS: 1621866-96-3 (AZD1208 hydrochloride)